Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overlap Syndrome Clear all
Recruiting No phase listed Observational

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

NCT07143669
View directory record Official record
Conditions
Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease
Interventions
Screening
Other
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Birmingham, Alabama • San Diego, California • Walnut Creek, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 4:03 AM EDT
Completed No phase listed Observational

Effect of Nasal CPAP on Cardiopulmonary Exercise Testing in Patients With Overlap Syndrome

NCT01033266
View directory record Official record
Conditions
Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease
Interventions
CPET
Diagnostic Test
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 2 Interventional

Pulmonary and Cardiac Effects of E-Cigarette Use in Pulmonary Patients Who Smoke Cigarettes

NCT05610514
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema, Asthma-COPD Overlap Syndrome
Interventions
E-Cigarette, Financial Incentives
Other · Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Jul 23, 2026, 4:03 AM EDT
Recruiting No phase listed Observational

Musculoskeletal and Pelvic Floor Health in Female Chronic Overlapping Pelvic Pain Conditions

NCT05750212
View directory record Official record
Conditions
Chronic Pelvic Pain Syndrome
Interventions
Tone, Tenderness, Contraction, Relaxation, Electromyography, Transperineal, Pressure
Diagnostic Test
Lead sponsor
Loyola University
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jul 23, 2026, 4:03 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Pathophysiology of the Upper Airway in Patients With COPD and Concomitant OSA

NCT02567448
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Sleep and pulmonary physiologic measurements
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Jul 23, 2026, 4:03 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Cardiac Hemodynamics in Overlap Syndrome (COPD With Obstructive Sleep Apnea)

NCT01261377
View directory record Official record
Conditions
Chronic Obstructive Airway Disease
Interventions
Bi-level positive airway pressure (BPAP), Oxygen, CPAP
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Not applicable Interventional Results available

Monitoring and Peer Support to Improve Treatment Adherence and Outcomes

NCT03446768
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea
Interventions
Peer support, Online platform, Respiratory Therapist support
Other
Lead sponsor
COPD Foundation
Other
Eligibility
40 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Jul 23, 2026, 4:03 AM EDT
Recruiting Not applicable Interventional

EPPIC: Easing Pelvic Pain Interventions Clinical Research Program

NCT05127616
View directory record Official record
Conditions
Urologic Chronic Pelvic Pain Syndrome (UCPPS), Interstitial Cystitis, Bladder Pain Syndrome, Chronic Prostatitis, Chronic Pain, Chronic Pelvic Pain Syndrome, Chronic Overlapping Pain Disorders
Interventions
Minimal Contact-Cognitive Behavior Therapy, Patient Education/Support
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jul 23, 2026, 4:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

NCT06523556
View directory record Official record
Conditions
Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Myeloproliferative Neoplasm
Interventions
Axatilimab, Azacitidine, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Survey Administration
Biological · Drug · Procedure + 1 more
Lead sponsor
Uma Borate
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 2 Interventional

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder

NCT00274820
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
ascorbic acid, arsenic trioxide, dexamethasone, thalidomide
Dietary Supplement · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 2 Interventional

Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)

NCT02302417
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Spirometry, ACOS clinical questionnaire
Procedure · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
12
States / cities
Newport Beach, California • Upland, California • Sunset, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

NCT00230178
View directory record Official record
Conditions
Tumor Lysis Syndrome, Cancer, Hyperuricemia
Interventions
Rasburicase (SR29142), Allopurinol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
15
States / cities
Berkeley, California • Los Angeles, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Jul 23, 2026, 4:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

NCT04061421
View directory record Official record
Conditions
MDS/MPN
Interventions
ASTX727, Itacitinib, Ruxolitinib
Drug
Lead sponsor
Michael Savona
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Tampa, Florida • Rochester, New York • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 23, 2026, 4:03 AM EDT
Active, not recruiting Phase 1 Interventional

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

NCT04279847
View directory record Official record
Conditions
Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm, Relapsed or Refractory Primary Myelofibrosis, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), ET (Essential Thrombocythemia)
Interventions
INCB057643, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 23, 2026, 4:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

Intermittent Hypoxia-initiated Plasticity in Humans: A Multi-pronged Therapeutic Approach to Treat Sleep Apnea and Overlapping Co-morbidities

NCT05558501
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Mild Intermittent Hypoxia, Sham MIH
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
30 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Jul 23, 2026, 4:03 AM EDT
Active, not recruiting Phase 2 Interventional

Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders

NCT04761770
View directory record Official record
Conditions
Myelodysplastic Syndrome, Myeloproliferative Neoplasms, Chronic Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Myelodysplastic/Myeloproliferative Overlapping Syndrome
Interventions
Geriatric assessment (GA) pre-transplant, conditioning regimen, Allogeneic CD34+ selected stem cells
Other · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 23, 2026, 4:03 AM EDT
Terminated No phase listed Observational

Connect® Myeloid Disease Registry

NCT01688011
View directory record Official record
Conditions
Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
Interventions
Luspatercept
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
2,013 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
155
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 131 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jul 23, 2026, 4:03 AM EDT
Recruiting Not applicable Interventional

The Effect of Interval Exercise on Functional Outcomes in Veterans With COPD and OSA

NCT05254431
View directory record Official record
Conditions
COPD, OSA
Interventions
Exercise
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Salem, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 1 Interventional

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

NCT05665530
View directory record Official record
Conditions
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
Interventions
PRT2527, Zanubrutinib, Venetoclax
Drug
Lead sponsor
Prelude Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Duarte, California • Bethesda, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jul 23, 2026, 4:03 AM EDT
Recruiting Not applicable Interventional

Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)

NCT04179981
View directory record Official record
Conditions
Sleep Apnea Syndrome, Obstructive Sleep Apnea, COPD, Overlap Syndrome, Quality of Life, Neurocognitive Function, Sleepiness, Elderly, Positive Airway Pressure
Interventions
Positive airway pressure, Conservative care (control arm)
Device · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 4:03 AM EDT
Recruiting Phase 1 Interventional

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

NCT06138587
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Myeloproliferative Disorders
Interventions
Cytokine Induced Memory-like Natural Killer Cells, Interleukin-2
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 4:03 AM EDT
Not listed Phase 3 Interventional

Continuous Positive Airway Pressure Versus Noninvasive Ventilation in Patients With Overlap Syndrome

NCT01427673
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, Overlap Syndrome
Interventions
Bipap procedure
Procedure
Lead sponsor
United States Air Force
Federal
Eligibility
35 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Wpafb, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 31, 2011 · Synced Jul 23, 2026, 4:03 AM EDT
Recruiting Early Phase 1 Interventional

Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

NCT07071155
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Overlap Neoplasms, Chronic Neutrophilic Leukemia
Interventions
Momelotinib, Azacitidine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 23, 2026, 4:03 AM EDT
Recruiting Phase 1 Interventional

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

NCT05549661
View directory record Official record
Conditions
Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified, Recurrent Atypical Chronic Myeloid Leukemia, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Myelodysplastic/Myeloproliferative Neoplasm
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Onvansertib, Ultrasound Imaging
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 23, 2026, 4:03 AM EDT